Vimarsana
Biggest News Aggregation in the World

Stephend Miller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stephend Miller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stephend Miller Today - Breaking & Trending Today

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis - Vimarsana News

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

Published: January 10, 2022

/PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced...

Source: prnewswire.com
Related Topics:
Northwestern UniversityUnited StatesJohn PuisisJulie FergusonStephend MillerIronwood Pharmaceuticals IncDrug AdministrationJudye Guggenheim Research Professor Of MicrobiologyFast Track DesignationPrimary BiliaryTrack DesignationAccelerated ApprovalIronwood PharmaceuticalsResearch ProfessorCour Pharmaceuticals
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis - Vimarsana News

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

Published: January 10, 2022

/PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced...

Source: prnewswire.com
Related Topics:
Northwestern UniversityUnited StatesJohn PuisisJulie FergusonStephend MillerIronwood Pharmaceuticals IncDrug AdministrationJudye Guggenheim Research Professor Of MicrobiologyFast Track DesignationPrimary BiliaryTrack DesignationAccelerated ApprovalIronwood PharmaceuticalsResearch ProfessorCour Pharmaceuticals
U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC) - Vimarsana News

U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)

Published: October 4, 2021

/PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders today announced...

Source: prnewswire.com
Related Topics:
United StatesNorthwestern UniversityJohn PuisisJulie FergusonM Eric GershwinStephend MillerJudye Guggenheim Research Professor Of MicrobiologyProfessor Of Medicine At University CaliforniaTakeda Pharmaceutical CompanyPrimary Biliary CholangitisImmune ReprogramingDistinguished ProfessorResearch ProfessorCour Pharmaceuticals